Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action

Cells. 2020 Jul 26;9(8):1781. doi: 10.3390/cells9081781.

Abstract

Lubiprostone, a 20-carbon synthetic fatty acid used for the treatment of constipation, is thought to act through an action on Cl- channel ClC-2. Short chain fatty acids (SCFAs) are produced and absorbed in the distal intestine. We explore whether SCFAs affect ClC-2, re-examine a possible direct effect of lubiprostone on ClC-2, and use mice deficient in ClC-2 to stringently address the hypothesis that the epithelial effect of lubiprostone targets this anion channel. Patch-clamp whole cell recordings of ClC-2 expressed in mammalian cells are used to assay SCFA and lubiprostone effects. Using chamber measurements of ion current in mice deficient in ClC-2 or CFTR channels served to analyze the target of lubiprostone in the distal intestinal epithelium. Intracellular SCFAs had a dual action on ClC-2, partially inhibiting conduction but, importantly, facilitating the voltage activation of ClC-2. Intra- or extracellular lubiprostone had no effect on ClC-2 currents. Lubiprostone elicited a secretory current across colonic epithelia that was increased in mice deficient in ClC-2, consistent with the channel's proposed proabsorptive function, but absent from those deficient in CFTR. Whilst SCFAs might exert a physiological effect on ClC-2 as part of their known proabsorptive effect, ClC-2 plays no part in the lubiprostone intestinal effect that appears mediated by CFTR activation.

Keywords: CFTR; ClC-2; butyrate; intestinal electrolyte transport; lubiprostone; short chain fatty acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CLC-2 Chloride Channels
  • Chloride Channel Agonists / pharmacology
  • Chloride Channel Agonists / therapeutic use*
  • Chloride Channels / drug effects*
  • Fatty Acids, Volatile / metabolism*
  • HEK293 Cells
  • Humans
  • Intestinal Mucosa / drug effects*
  • Lubiprostone / pharmacology
  • Lubiprostone / therapeutic use*

Substances

  • CLC-2 Chloride Channels
  • Chloride Channel Agonists
  • Chloride Channels
  • Fatty Acids, Volatile
  • Lubiprostone